Data gathered: May 30
AI Stock Analysis - Axsome Therapeutics (AXSM)
Analysis generated March 20, 2025. Powered by Chat GPT.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for the treatment of central nervous system (CNS) disorders. The company's pipeline includes products designed to address conditions such as depression, migraines, and other neurological and psychiatric ailments. With a strong emphasis on innovation and addressing significant unmet medical needs, Axsome has positioned itself as a key player in the CNS therapeutic market.
Stock Alerts - Axsome Therapeutics (AXSM)
 |
Axsome Therapeutics | May 30 Insider Alert: Coleman Mark is continuing selling shares |
|
Axsome Therapeutics | May 29 Insider Alert: Jacobson Mark L. is selling shares |
|
Axsome Therapeutics | May 27 Employee Rating is up by 3.1% over the last month. |
|
Axsome Therapeutics | May 21 Insider Alert: Coleman Mark is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Axsome Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 31 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 25,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| Patents | 243 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 37 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 11,735 | Sign up | Sign up | Sign up |
| Twitter Followers | 527 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 702 | Sign up | Sign up | Sign up |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Price | $104.81 |
| Target Price | Sign up |
| Volume | 42,190 |
| Market Cap | $5.07B |
| Year Range | $80.05 - $137.75 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Axsome Therapeutics to Participate in Upcoming Investor ConferencesMay 29 - Financial Post |
|
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 28 - Financial Post |
|
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.May 27 - GlobeNewswire |
|
 |
Cetera Investment Advisers Has $601,000 Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)May 27 - ETF Daily News |
Axsome Therapeutics Settles Sunosi Patent Litigation With Hetero LabsMay 26 - Finnhub |
|
|
Nuveen Asset Management LLC Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)May 25 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 121M | 9.8M | 112M | -59M | -57M | 0.000 |
| Q4 '24 | 119M | 11M | 108M | -75M | -71M | -1.540 |
| Q3 '24 | 105M | 8.4M | 96M | -65M | -61M | -1.342 |
| Q2 '24 | 87M | 8.1M | 79M | -79M | -78M | -1.670 |
| Q1 '24 | 75M | 8.1M | 67M | -68M | -65M | -1.440 |
Insider Transactions View All
| Coleman Mark filed to sell 46,637 shares at $103.4. May 29 '25 |
| Jacobson Mark L. filed to sell 5,783 shares at $103.5. May 28 '25 |
| Jacobson Mark L. filed to sell 5,783 shares at $104.7. May 28 '25 |
| Coleman Mark filed to sell 54,137 shares at $107.5. May 20 '25 |
| Pizzie Nick filed to sell 42,187 shares at $131.1. February 14 '25 |
Similar companies
Read more about Axsome Therapeutics (AXSM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Axsome Therapeutics?
The Market Cap of Axsome Therapeutics is $5.07B.
What is the current stock price of Axsome Therapeutics?
Currently, the price of one share of Axsome Therapeutics stock is $104.81.
How can I analyze the AXSM stock price chart for investment decisions?
The AXSM stock price chart above provides a comprehensive visual representation of Axsome Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Axsome Therapeutics shares. Our platform offers an up-to-date AXSM stock price chart, along with technical data analysis and alternative data insights.
Does AXSM offer dividends to its shareholders?
As of our latest update, Axsome Therapeutics (AXSM) does not offer dividends to its shareholders. Investors interested in Axsome Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Axsome Therapeutics?
Some of the similar stocks of Axsome Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.